MedTrace Logo

A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

NCT04592523 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 257

Last updated 2025-12-24

No results posted yet for this study

Summary

The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Anaplastic Lymphoma Kinase

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2026-08-26
Completion
2026-08-26
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04592523 on ClinicalTrials.gov